CHÂTILLON, France, June 8, 2026
DBV Technologies announced new positive clinical findings from its Phase 3 VITESSE study evaluating the VIASKIN® Peanut Patch in children aged 4 to 7 years with peanut allergy, alongside a preview of the recently initiated Phase 2 THRIVE study in infants aged 6 to 12 months. The data will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 in Istanbul, Turkey. The latest results reinforce the potential of the company’s proprietary epicutaneous immunotherapy (EPIT) platform as a non-invasive treatment approach designed to improve peanut tolerance while addressing the significant unmet needs of patients living with food allergies and associated allergic conditions.
VITESSE Study Demonstrates Strong Efficacy Across Atopic Conditions
The Phase 3 VITESSE trial evaluated the efficacy and safety of the VIASKIN Peanut Patch in 654 children with peanut allergy, many of whom also suffered from common allergic comorbidities such as asthma, additional food allergies, and atopic dermatitis. Results showed that significantly more participants receiving the patch achieved the study’s response criteria at 12 months compared with placebo across all major subgroup analyses. Among children with asthma, response rates reached 48.3% compared to 19.6% for placebo, while participants with additional food allergies achieved response rates of 46.8% versus 13.6%. Children with atopic dermatitis demonstrated similarly strong outcomes, with response rates of 47.2% compared to 13.2% in the placebo group. These findings closely mirrored the overall study population, where 46.6% of treated children met response criteria versus 14.9% receiving placebo, highlighting the consistency of treatment benefit across diverse patient groups.
Addressing a Major Unmet Need in Pediatric Peanut Allergy
Peanut allergy is one of the most common and potentially life-threatening food allergies worldwide, often occurring alongside other allergic diseases that can complicate management and increase healthcare burden. The VITESSE subgroup analysis is particularly important because more than half of enrolled participants had additional food allergies or atopic dermatitis, while over one-third had asthma. According to DBV Technologies, the positive outcomes demonstrate that the VIASKIN Peanut Patch maintained statistically significant efficacy regardless of accompanying allergic conditions, supporting its potential use in real-world patient populations where multiple atopic disorders frequently coexist. The therapy’s non-invasive administration through intact skin may offer an attractive alternative to more burdensome treatment approaches while helping patients gradually build tolerance to peanut exposure.
Advertisement
THRIVE Study Explores Early Intervention in Infants
In addition to the VITESSE results, DBV Technologies unveiled details of its newly launched THRIVE Phase 2 study, which is designed to investigate the benefits of earlier intervention in infants aged 6 to 12 months with physician-confirmed peanut allergy. The open-label study plans to enroll approximately 250 infants and will evaluate whether participants can achieve ad lib consumption of peanuts after three years of treatment with the VIASKIN Peanut Patch. Researchers believe that infants may possess greater immune system flexibility, potentially allowing earlier immunotherapy to generate more durable immune tolerance. If successful, THRIVE could provide valuable evidence supporting early treatment strategies and may influence future clinical practice guidelines for managing peanut allergy in very young children.
Epicutaneous Immunotherapy Advances Food Allergy Treatment
At the core of DBV Technologies’ development program is its proprietary epicutaneous immunotherapy (EPIT) platform, which delivers controlled microgram quantities of allergen through the skin to help retrain the immune system without invasive procedures. Unlike traditional approaches that often require oral allergen exposure, EPIT leverages the skin’s natural immune-regulating properties to promote desensitization while maintaining a favorable safety profile. The company believes the VIASKIN Peanut Patch could become an important treatment option for patients across multiple age groups, from infants to school-aged children, if approved by regulatory authorities. With ongoing clinical development and expanding evidence from both VITESSE and THRIVE, DBV Technologies continues to strengthen its position in the growing field of food allergy immunotherapy, targeting a condition that affects millions of children and families worldwide.
Source: DBV Technologies press release
